Given the increased attention by clinicians, researchers and the pharmaceutical
industry to the management and treatment of dementia not only in the elderly but
also in increasingly younger populations, the demands for effective
evidence-based pharmaceutical control of dementia and quantitative assessment of
outcomes have increased. Since some first steps in the early 1960's to the
controversial landmark paper of Summers and colleagues, to the most recent
trials, it is clear both that much progress has been made, and that much remains
to be done. This book is written to take stock of what is now usefully known,
and to speculate on directions for the future. Short Contents